Aura Biosciences, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $30.7M | — | $28.0M | — | — | — | $22.2M |
| SG&A Expense | — | $17.3M | — | $6.9M | — | — | — | $5.7M |
| Operating Income | — | $-48.1M | — | $-34.9M | — | — | — | $-27.9M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-45.6M | — | $-33.7M | — | — | — | $-26.1M |
| Income Tax Expense | — | $29.0K | — | $11.0K | — | — | — | $26.0K |
| Net Income | — | $-45.6M | — | $-33.7M | — | — | — | $-26.1M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.48 | — | $-0.50 | — | — | — | $-0.40 |
| EPS (Diluted) | — | $-0.48 | — | $-0.50 | — | — | — | $-0.40 |
| Shares Outstanding (Basic) | 103.7M | 94.9M | 103.4M | 67.4M | 64.2M | 63.6M | 63.5M | 65.9M |
| Shares Outstanding (Diluted) | 103.7M | 94.9M | 103.4M | 67.4M | 64.2M | 63.6M | 63.5M | 65.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |